# HSEF v5.3 review: Chronic Inflammation as Root Cause of Aging

> Sources: 69 primary reports; claims: 73; verified: 73; unverified: 0. Verification is bounded attribution. Access: 4 partial-body and 65 complete abstract/status examinations. Cutoff: 2026-10-05. No complete-paper audit or blinded calibration claimed.
> **Adversarial review:** Generated by Sol 6.1; adversarially reviewed by Claude Opus 5.5 (Anthropic) on 2026-10-06. 2 corrections applied (see ADVERSARIAL REVIEW AND APPROVAL). Status: **Approved as revised.**

## AT A GLANCE

**Inflammatory pathways causally amplify defined age-related pathologies; autonomous primary initiation of normal organismal aging remains unproved.**

| Level | Confidence | Causal role | Momentum | Stability | Divergence |
|---|---|---|---|---|---|
| Β — Associational | Moderate | reinforcing / stabilizing factor | Decisive work underway | Stable | Contested |

**Deciding experiment:** Independent-site adult mammalian factorial experiment that blocks a defined inflammatory cell circuit before its rise, reinstates its mediator and crosses it with independently induced upstream DNA/mitochondrial damage; translate to a prespecified multi-year clinical function endpoint.

**Belief versus evidence:** The registered weakest-link bundle scores Β, bound by the observational age-relationship SC1. The causal-pathology sensitivity is Ζ and the primary-initiation sensitivity Γ. A bundle score is not a verdict that inflammatory biology is imaginary or causally inert.

**Best-supported rival:** Damage-triggered immune reinforcement. Timed cell-specific blockade before measured damage, combined with restoration of the inflammatory mediator and independently induced upstream damage, can distinguish initiation from reinforcement.

## COMPETING MECHANISTIC MODELS

**Rank 1: Damage-triggered immune reinforcement (Ζ).** Misplaced DNA, injury and metabolic stress recruit immune circuits that feedback on dysfunction. Damage-to-cGAS/NFkB pathways and selected blockade benefits converge. Initiating lesions vary by organ and population.

**Rank 2: Senescence-origin signaling (Ε).** Persistent stressed cells supply secreted or chromatin signals that propagate pathology. Transfer, miMOMP and chromatin experiments support defined circuits. Clearance changes more than secretory inflammation.

**Rank 3: Environmental and exposome contingency (Γ).** Infection ecology, market integration and behavior shape inflammatory aging patterns. Cross-population axes and social variation support context dependence. Cross-sectional ecology does not isolate particular causal exposures.

**Rank 4: Failure of resolution (Ε).** Incomplete resolution and homeostatic immune support exacerbate tissue dysfunction. FPR2 loss and STING homeostasis indicate protective functions. Severe early knockout phenotypes are not normal-aging rate evidence.

**Rank 5: Autonomous inflammation-first aging (Γ).** Low-grade inflammation is the initiating central driver of normal aging. Engineered inflammatory states can accelerate decline and some late interventions extend mouse life. Antecedence, universal necessity and independence from upstream damage are not demonstrated.

The tournament does not alter the nominal level. Compatible pathways and flexible alternatives are not automatically proved by explaining observations.

## FULL REVIEW

### Registered claim and scope

Chronic low-grade inflammation is an autonomous primary initiating driver of organismal aging rather than predominantly a consequence or amplifier of upstream damage.

Use the index weakest-link rule for inflammatory presence, causal contribution and autonomous primacy. Specific disease-modifying biologics and mouse lifespan effects remain distinct from inflammation as a root cause of human organismal aging.

Selection: public-interest rank 14 from the editorial ranking compiled 2026-09-23; categorical prior verdicts were visible. Private fresh review; earlier documents are preserved.

### Evidence and causal interpretation

Inflammation can drive selected phenotypes. NLRP3 loss affects multi-organ functions; adult hypothalamic gain/loss experiments change survival with pair-feeding and vector controls. Original IL11 passages confirm late antibody survival benefit, separate healthspan dosing, partly incomplete genetic follow-up and gross tumor reductions. These are intervention levers, with different normal-aging, developmental and disease scopes [1,3,18,20,37,50,51].

Damage and feedback have direct mechanistic support. Mitochondrial permeabilization, misplaced chromatin, telomere dysfunction, microbial metabolites and senescent cell states can initiate immune responses that then reinforce injury. Engineered nfkb1 inflammation can itself cause damage, demonstrating feedback sufficiency; it does not identify the autonomous first event in normal aging [2,4,7,23,30,47,49,60,61,63,69].

Human inflammatory biomarkers often predict frailty and mortality, but their axes and age gradients are not universal. Original abstracts distinguish Tsimane minimal multi-marker inflammaging from retained IL6 increase, and heterogeneous population axis structure from total absence of tissue inflammation. Longitudinal immune reprogramming includes changes not attributed to systemic inflammation. Genetic surrogate estimates and prediction clocks do not establish a single causal aging rate [31–46,48,52,68].

Targeted IL1 blockade reduced recurrent cardiovascular events without lipid lowering in CANTOS; its all-cause mortality was null and fatal infection increased. CANTOS response and cancer analyses are one cohort. COLCOT and LoDoCo2 supply separate disease efficacy evidence. CIRT did not engage the specified inflammatory markers; CLEAR did lower CRP but remained clinically null. Neither positive nor negative disease trials alone establish normal-aging initiation [26,27,29,53–59].

Resolution and basal signaling can be protective. Original FPR2 Methods/Results reveal severe early male mortality with hyperphagia and comparisons to expected wild-type lifespan, constraining normal-aging inference. Physiological STING loss shortened mouse lifespan, and newer killifish and short-telomere studies provide signature/outcome and lesion-specific nulls. Timing, cell identity and pathway degree require explicit mapping [64–67].

## HYPOTHESIS STATE EVALUATION FRAMEWORK (HSEF v5.3)

<!-- consensus-consistency-2026-10-09 -->
### Consensus provenance reconciliation — 9 October 2026

Case-specific Consensus discovery records were located and linked to this final edition. This supplements the review's provenance; it leaves the original assessed claim, grades and source counts intact. Provider summaries and full-text badges do not establish examination of original primary passages by this reviewer. Source access and incorporation retain the limits stated in the original methods and any dated research update.

Recorded evidence artifacts:

- `deliverables/hsef_v53_popularity_ranks_11_15_2026-10-05/inflammaging-primary-driver/consensus-browser.png`
- `deliverables/hsef_v53_popularity_ranks_11_15_2026-10-05/inflammaging-primary-driver/consensus-countertests-search-log.json`
- `deliverables/hsef_v53_popularity_ranks_11_15_2026-10-05/inflammaging-primary-driver/consensus-deep.txt`
- `deliverables/hsef_v53_popularity_ranks_11_15_2026-10-05/inflammaging-primary-driver/consensus-dom.txt`
- `deliverables/hsef_v53_popularity_ranks_11_15_2026-10-05/inflammaging-primary-driver/consensus-pro-verification.txt`

The located artifacts do not state a reliable source-comparison count. No count is inferred.

A dated adversarial approval record exists for the separately identified inflammaging-primary-driver.review.md (2026-10-06; see edition-approval-audit.json). Its scope is that recorded edition. This supplement has no separate approval and no coverage is inferred from topic identity. No score or confidence change is made by this reconciliation.
<!-- end-consensus-consistency -->


### Subclaim matrix and aggregation

| Subclaim | Scope | Level | Decision |
|---|---|---|---|
| SC1 Inflammatory signals are elevated with normal age. | normally aging mammals and human cohorts | Β | Inflammatory age relationships recur in selected cohorts but are observational, sex-dependent and nonuniversal across measured populations. |
| SC2 Chronic low-grade inflammation contributes causally to age-related pathology. | prespecified age-related disease phenotypes and normally aged mammals | Ζ | Targeted human IL1 blockade, IL6R genetic evidence and conditional/adult animal perturbations converge on causal contribution to prespecified disease and functional endpoints. |
| SC3 Inflammation is an autonomous primary driver of organismal aging. | normal organismal aging across tissues, with human inference explicit | Γ | Damage-responsive activation and contextual intervention effects do not establish autonomous antecedence, necessity or rate limitation across normal organismal aging. |

Preregistered aggregation: weakest-link. The registered weakest-link bundle scores Β, bound by the observational age-relationship SC1. The causal-pathology sensitivity is Ζ and the primary-initiation sensitivity Γ. A bundle score is not a verdict that inflammatory biology is imaginary or causally inert. Sensitivities: weakest-link Β; primary-subclaim Γ; scope-matched Γ.

### Decisive-perturbation inventory and causal tally

[1] STING blockade improves selected aged functions; mtDNA links damage to signaling Does not show autonomous initiation or organismal lifespan

[2] Sublethal mitochondrial permeabilization supplies DNA for SASP and functional effects Upstream apoptotic stress remains; linked correction details unexamined

[3] Late antibody and genetic intervention improve survival and selected functions One background and incomplete genetic survival follow-up do not prove universal primacy

[4] DNA damage GATA4 autophagy and NFkB connect injury to SASP Does not establish organismal necessity

[5] Human immune changes and mouse targeted metabolic effects converge Human CR is pleiotropic and mediator lifespan not tested

[7] Microbial ADP-heptose ALPK1 stimulates mutant expansion Does not establish autonomous aging initiation

[8] Ibuprofen improves cognition in engineered inflammatory context Broad drug and knockout model do not establish normal-aging primacy

[9] Microbiota change lineage aging despite nonuniform inflammatory signatures Germ-free development and ecology differ

[10] Persistent NFkB affects telomeres and muscle dysfunction Chronic injury scope is distinct from normal organismal aging

[11] Timed Relish and PTTH manipulation affects life and inflammatory programs Developmental timing is a separate upstream intervention

[12] Intrinsic NFkB and inflammatory niche drive distinct HSC defects Elevated signaling is not sufficient for every aging hallmark

[13] Fibroblast NFkB and GZMK T-cell depletion alter injury vulnerability Does not establish systemic aging initiation or life extension

[14] TNF-A20 mechanism links chronic inflammation to weak antibacterial response Diet and local response do not isolate whole-organism aging

[15] SIRT7 loss and chromatin binding connect senescence to inflammation Not a lifespan or primary-initiation test

[16] TLR4 deficiency attenuates induced cognitive phenotypes Injected B2M model and unexamined erratum limit scope

[18] Cell-specific perturbation alters insulin resistance Developmental and metabolic context not systemic aging initiation

[20] Persistent activation drives local dysfunction partially reversible on cessation Selected neural scope not autonomous organismal aging

[22] Midlife IMD repression extends life with TOR-related sex effects mTOR and lysosomal context remain upstream or interacting

[23] Senescence produces hyperinflammatory adhesion and faster atherosclerosis Progeroid injury precedes response and is not normal-aging primacy

[26] Colchicine lowers CRP but primary cardiovascular outcome is null Clinical disease context and broad drug do not refute all inflammatory pathways

[30] Added burden and clearance affect function and remaining survival Does not isolate inflammation from all cell functions

[35] Nucleotide metabolites activate inflammasomes and selected vascular phenotypes Does not establish the primary aging trigger

[37] Knockout preserves cardiac features and survival Developmental male one-background result is not universal aging primacy

[40] Cytokine axes and age associations vary by population Chosen cytokine-axis nonuniversality does not prove absence of all tissue inflammation

[47] cGAS loss alters damage-induced senescence and immortalization Tumor suppression can be beneficial; cellular scope not systemic aging

[48] Some age-related T-cell reprogramming is not driven by systemic inflammation or CMV Does not rule out other inflammatory aging components; correction details unexamined

[49] Interaction-specific inhibition reduces selected inflammatory markers Marker reduction and tumor context do not prove life extension

[50] Defined sensor loss alters multi-organ aging functions with mediator differences Developmental deletion and upstream damage sensing do not prove autonomy

[51] Adult gain-loss contrasts affect survival and functions; GnRH branch implicated Region-specific potency and broad developmental knockout do not establish universal primacy

[52] Minimal selected inflammaging in Tsimane differs from market-integrated neighbors Mostly cross-sectional; IL6 still increases and tissue inflammation unmeasured

[53] Specific blockade reduces recurrent cardiovascular events without lipid lowering No all-cause survival benefit; infection harm and disease-selected scope

[56] Cardiovascular outcomes and specified inflammatory markers do not improve Without pathway engagement this is not a clean falsification of IL1 IL6 causality

[57] Colchicine reduces selected post-MI composite events Broad drug and pneumonia signal; not general aging efficacy

[58] Colchicine reduces chronic-coronary composite events No general healthy-life claim; noncardiovascular mortality uncertainty

[59] IL6R variant and biomarker pattern support coronary causal role Pooled original genetic analysis is not aging initiation or longevity proof

[60] Cytoplasmic chromatin triggers cGAS inflammation with surveillance role Upstream DNA and cancer context block autonomous-aging inference

[61] cGAS recognizes fragments and promotes paracrine senescence Damage precedes inflammation; no organismal-life test

[62] Genetic and drug NFkB suppression improve disc measures Shared progeroid platform and unexamined erratum limit generalization

[63] Genetic and drug inhibition reduce damage-driven aging phenotypes Upstream repair defect remains; not autonomous normal-aging initiation

[64] Resolution loss produces sex-specific obesity and early mortality Survival comparison includes assumed normal lifespan; severe early model not normal senescence

[65] Age signatures improve while lifespan remains unchanged Compensation and developmental loss differ from timed selective blockade

[66] STING deficiency shortens life and disrupts homeostasis Basal lifelong loss does not negate pathological late activation

[67] STING loss fails to rescue several degenerative and survival phenotypes Bounded telomerase context not all aging

[68] Tested IL6R allele does not predict survival to90 or major disease outcomes Single variant female cohort does not duplicate drug blockade or refute all inflammation causality

[69] Inflammatory genetic state causes ROS telomere feedback and reduced repair Engineered inflammation sufficiency does not establish normal-aging primary initiation

Tally: 45 discriminating contrasts. Null and negative contrasts are discriminators, not positive threshold crossings. Reports and replications are not independent causal lines. Shared cohorts, experimental platforms, transgenic lineages and repeated outcomes do not constitute fully independent causal lines.

### Cap audit, precedence and Β/Γ/Δ boundary

The immunology hard cap binds broad immunosuppression or ex vivo-only claims. It does not re-cap the convergent targeted clinical, allelic and cell-resolved causal set for SC2. The aging one-species boundary still constrains animal lifespan extrapolation, while SC3 lacks direct organismal-autonomy evidence. Β for the bundle reflects registered aggregation, not a denial of Ζ pathology contribution.

Gamma hard-rule audit: Biomarkers alone do not cross the aging-trajectory boundary. Species, strain, developmental timing and nonspecific interventions constrain the scope of each result.

SC1 cap: “Inflammation association without pathway-specific causality caps at Β.” Inflammatory age relationships recur in selected cohorts but are observational, sex-dependent and nonuniversal across measured populations.

SC1 field-valid definition: “
- Cell-type-specific conditional knockout or depletion
- Pathway-specific blockade (not broad immunosuppression) changing disease course
- Human targeted therapy with mechanistic alignment showing disease-modifying effect” Positive full-scope result: no. Inflammatory age relationships recur in selected cohorts but are observational, sex-dependent and nonuniversal across measured populations.

SC2 field-valid definition: “
- Cell-type-specific conditional knockout or depletion
- Pathway-specific blockade (not broad immunosuppression) changing disease course
- Human targeted therapy with mechanistic alignment showing disease-modifying effect” Positive full-scope result: yes. Targeted human IL1 blockade, IL6R genetic evidence and conditional/adult animal perturbations converge on causal contribution to prespecified disease and functional endpoints.

SC3 field-valid definition: “
- Cell-type-specific conditional knockout or depletion
- Pathway-specific blockade (not broad immunosuppression) changing disease course
- Human targeted therapy with mechanistic alignment showing disease-modifying effect” Positive full-scope result: no. Damage-responsive activation and contextual intervention effects do not establish autonomous antecedence, necessity or rate limitation across normal organismal aging.

### Upward threshold ladder

SC1 Δ: “Requires pathway- or cell-type-resolved causal perturbation affecting disease or phenotype.” Satisfied: no. Broader age-pattern generalization requires standardized repeated tissue and blood measurements across diverse ecologies with infection and composition controls; association alone remains observational.

SC2 Δ: “Requires pathway- or cell-type-resolved causal perturbation affecting disease or phenotype.” Satisfied: yes. 

SC2 Ε: “Requires context-specific causality with explicit scope restriction.” Satisfied: yes. 

SC2 Ζ: “Requires multiple convergent causal manipulations and reduced plausibility of downstream-only interpretations.” Satisfied: yes. 

SC2 Η: “Requires robust upstream causal evidence across systems and interventions.” Satisfied: no. Independent targeted replication and prospective mediator-specific rescue across additional disease contexts would support Η.

SC3 Δ: “Requires pathway- or cell-type-resolved causal perturbation affecting disease or phenotype.” Satisfied: no. Demonstrate pre-damage inflammatory onset, selective prevention of multisystem aging and necessity/rescue without inducing a separate developmental or metabolic lesion.

Upper ladder: Ζ is reached for defined causal pathology contribution by complementary human and animal lines. Η and above remain live, but the wide age-pathology scope, single-target clinical evidence, heterogeneous contexts and lack of organismal initiation tests limit further ascent. Primary normal-aging autonomy cannot borrow atherothrombosis efficacy.

Independence: Complementary methods cover different errors for scoped contribution. CANTOS follow-ups are one randomized population; response-defined subsets are not randomized causal replication. Progeroid and nfkb1 follow-ups share platforms. Tsimane cohorts may overlap and are not two independent demonstrations.

Targeted clinical blockade [53]: Separates IL1 contribution from lipid lowering in residual-risk coronary disease.

Human allelic instrument [59]: Addresses some treatment and confounding explanations for coronary contribution.

Timed/cell-resolved animal contrasts [51, 20, 3]: Reduces solely associative and partly developmental explanations.

Upstream-signal and countercontext tests [2, 60, 66, 65]: Distinguishes damage sensing from autonomous initiation and broad suppression.

### Falsification and pitfalls

Proposed universal inflammatory aging pattern is absent. Selected Tsimane/Orang Asli cytokine axes are not age-associated; this rejects a universal measurement pattern but not all local inflammation. Additional downgrade: False.

Inflammatory engagement or signature reduction without outcome improvement. CLEAR CRP reduction with clinical null and killifish signature reduction with lifespan null. Additional downgrade: False.

Inflammatory pathway maintains useful homeostasis. Lifelong STING loss shortens mouse survival; chromosome-sensing pathways contribute tumor surveillance. Additional downgrade: False.

Inflammation presence mistaken for initiation. SC1 and SC3 are separated from contribution.

Biomarker suppression mistaken for aging-rate change. CLEAR, clocks and killifish results retain functional/survival endpoints.

Trial subgroup conditioning mistaken for mediation. CANTOS achieved CRP/IL6 and CHIP analyses are same-cohort exploratory or secondary reports.

Cancer delay excluded without evidence. IL11 gross tumor reductions are retained; lifespan mediation unresolved.

Ecological nonuniversality made absolute. Selected cytokine axes differ and IL6 still rises in Tsimane.

### Adversarial steelman: above, then below

Η for SC2 would require broader independently replicated targeted convergence. Δ for autonomy requires a scope-matched initiation discriminator, not simply another late-life disease intervention. The bundle cannot rise above Β while retaining its observational existence subclaim.

Γ for defined pathology contribution would ignore targeted human clinical efficacy plus genetic and timed animal contrasts. Α for the bundle would ignore reproducible cohort relationships despite ecological heterogeneity.

Retain Β bundled, Ζ scoped contribution and Γ autonomous primacy, keeping disease and aging endpoints explicit.

### Final score, causal direction and M/S/D

The registered weakest-link bundle scores Β, bound by the observational age-relationship SC1. The causal-pathology sensitivity is Ζ and the primary-initiation sensitivity Γ. A bundle score is not a verdict that inflammatory biology is imaginary or causally inert.

Some signals follow damage, yet specific perturbation and inflammatory gain-of-function establish feedback causality, preventing a purely downstream or noncausal role under steps1–2. Initiation, prevention and rate limitation across normal aging are not all shown, nor universal necessity under steps3–4. Persistent circuits reinforce damage and dysfunction, meeting step5.

Momentum: Decisive work underway. IL11 antibody lifespan2024, human ecological studies2025, fibroblast circuitry2026 and killifish/telomerase countertests2026 are named active boundary work.

Stability: Stable. No named pending result is asserted to be likely to move the registered score imminently.

Divergence: Contested; no single implied-level arithmetic. These dimensions do not change level or confidence.

## PROPOSED DECISIVE EXPERIMENTS

Independent-site adult mammalian factorial experiment that blocks a defined inflammatory cell circuit before its rise, reinstates its mediator and crosses it with independently induced upstream DNA/mitochondrial damage; translate to a prespecified multi-year clinical function endpoint.

Readout: Time-resolved upstream damage, inflammatory engagement, multi-organ function and survival; patient disability or incident disease instead of a clock alone. Controls: Cell-specific and drug-resistant rescue controls, developmental exclusion, exposure/background/sex replication, infection surveillance and blinded endpoint adjudication. Supporting: Selective pre-damage intervention prevents broad aging despite upstream lesion exposure and rescue restores it. Falsifying: Damage and aging proceed despite selective suppression or benefit remains limited to one disease endpoint.

## RESEARCH TIMELINE

| Year | Milestone | Primary source | Interpretation |
|---|---|---|---|
| 2005 | Cell-specific IKK metabolic effects | [PMID15685170](https://pubmed.ncbi.nlm.nih.gov/15685170/) | Defined pathology contribution |
| 2009 | Function and inflammatory biomarkers | [PMID19196644](https://pubmed.ncbi.nlm.nih.gov/19196644/) | Human association |
| 2012 | DNA-damage NFkB interventions | [PMID22706308](https://pubmed.ncbi.nlm.nih.gov/22706308/) | Damage-response feedback |
| 2012 | IL6R genetic consortium | [PMID22421340](https://pubmed.ncbi.nlm.nih.gov/22421340/) | Coronary causal instrument |
| 2013 | NLRP3 aging perturbation | [PMID24093676](https://pubmed.ncbi.nlm.nih.gov/24093676/) | Multi-organ mouse contribution |
| 2013 | Hypothalamic gain/loss | [PMID23636330](https://pubmed.ncbi.nlm.nih.gov/23636330/) | Timed neuroendocrine intervention |
| 2014 | Chronic inflammation feedback | [PMID24960204](https://pubmed.ncbi.nlm.nih.gov/24960204/) | Engineered sufficiency |
| 2017 | CANTOS | [PMID28845751](https://pubmed.ncbi.nlm.nih.gov/28845751/) | Targeted clinical efficacy with infection harm |
| 2017 | Chromatin immune sensing | [PMID28976970](https://pubmed.ncbi.nlm.nih.gov/28976970/) | Upstream damaged material |
| 2019 | CIRT and COLCOT | [PMID30415610](https://pubmed.ncbi.nlm.nih.gov/30415610/) | Pathway engagement and outcome distinction |
| 2020 | LoDoCo2 | [PMID32865380](https://pubmed.ncbi.nlm.nih.gov/32865380/) | Coronary secondary prevention |
| 2023 | Aged-brain cGAS-STING | [PMID37532932](https://pubmed.ncbi.nlm.nih.gov/37532932/) | mtDNA-upstream functional contribution |
| 2024 | IL11 intervention | [PMID39020175](https://pubmed.ncbi.nlm.nih.gov/39020175/) | Late mouse survival benefit |
| 2024 | STING homeostasis | [PMID38645182](https://pubmed.ncbi.nlm.nih.gov/38645182/) | Basal protective boundary |
| 2025 | CLEAR published outcome | [PMID39555823](https://pubmed.ncbi.nlm.nih.gov/39555823/) | CRP reduction with clinical null |
| 2025 | Cytokine-axis nonuniversality | [PMID40588649](https://pubmed.ncbi.nlm.nih.gov/40588649/) | Human ecology boundary |
| 2026 | Killifish cGAS loss | [PMID42717099](https://pubmed.ncbi.nlm.nih.gov/42717099/) | Signature benefit without longer life |

## KNOWLEDGE GAPS

Which inflammatory circuit rises before any measurable upstream damage in naturally aging tissues?

Which lifelong homeostatic functions must be preserved while inhibiting late pathological cGAS-STING or NFkB activation?

Will independently replicated IL11 intervention improve complete functional trajectories after cancer-related survival mediation and background ecology are accounted for?

Which biomarkers transport across nonindustrialized populations and predict within-person tissue dysfunction rather than infection or cell composition?

Can clinical benefit be prospectively predicted without conditioning on achieved post-treatment inflammatory response?

Which inflammatory pathways affect survival, functional aging and surrogate clocks differently, and why do target-engaged nulls occur?

## METHODS AND CONSENSUS CONTRIBUTION

Consensus was used through the signed-in browser for discovery, counterevidence, research-gap and timeline suggestions, and attempted checks of specific indexed full-text passages. Returned Methods/Results passages were reconciled with original-paper passages where available; failed retrievals, source substitutions and unverified aspects are recorded in the case reconciliation. Successful passage checks are distinguished from provider summaries. Provider screening counts, citation counts and meters were not used as primary counts or HSEF scores. This source log records access depth; it does not claim complete-paper or supplement review. The monthly API allowance was conserved: zero Consensus API calls in this batch.

## REVIEWER NOTES

69 primary reports examined; four have selected original-body passages examined. Five newer countertests were located through Consensus and independently verified. Electronic dates for killifish and telomerase 2026 originals precede the review cutoff. Original IL6R consortium analysis is pooled primary genetic evidence, not a secondary narrative review. Detailed linked errata for miMOMP, B2M/TLR4, disc degeneration and human immune atlas were not examined. No formal concern was established for IL11 or the hypothalamic landmark from the retrieved status metadata; provider assurances are not a comprehensive misconduct audit.

Search leads, reviews, protocols and correction notices do not pad the primary count. Downloaded XML does not earn examination credit. Linked notices remain attached; unexamined correction details limit inference. This is a coordinator source/claim consistency assessment, not independent blinded calibration.

## ADVERSARIAL REVIEW AND APPROVAL

**Authoring model:** Sol 6.1. **Adversarial reviewer:** Claude Opus 5.5 (Anthropic). **Date:** 2026-10-06.

**Scope of checks.** All 69 reference PMIDs verified against PubMed metadata (title, first author, year, journal, DOI) — 69/69 resolve to the stated record; none carries a retraction or expression of concern. Ten load-bearing claims were spot-checked against the cited abstracts or retained original passages (CANTOS: event reduction without lipid lowering, the null all-cause mortality and the excess fatal infection; the CRP-reduction and CHIP analyses as same-cohort secondary or exploratory work; the IL6R Mendelian randomisation instrument and its coronary odds ratio; CIRT's failure to lower the specified markers; the cGAS-STING ageing study; neuron-specific IKK/NF-κB activation; NLRP3 loss; the FPR2 resolution-sensor model; the STING-deficiency longevity report). Scoring logic was re-derived from `references/hsef-framework.md` and SKILL.md Steps 3, 8–12: universal cap 2 binds SC1 at Β, the index-prescribed weakest-link rule is applied as written (Β from SC1 Β, SC2 Ζ, SC3 Γ), and the reported alternatives (primary-subclaim Γ, scope-matched Γ) are arithmetically correct for this matrix.

**Findings.**

| # | Severity | Location | Original → corrected | Evidence |
|---|---|---|---|---|
| F1 | Editorial | REFERENCES 59 and the matching `citation_ledger` entry | ", Swerdlow DI, Holmes MV et al." → "Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium, Swerdlow DI, Holmes MV et al." | Collective author dropped by the reference builder; PMID 22421340 carries the IL6R MR Consortium collective byline. |
| F2 | Minor | Evidence card [66] and its `citation_ledger` entry | `kind: "primary"` → `kind: "preprint"`; card access line now states that the record is a bioRxiv preprint and is not used to carry a threshold crossing | PubMed record for PMID 38645182 lists publication type "Preprint" (bioRxiv, DOI 10.1101/2024.04.04.588107). The score-card schema provides a distinct `preprint` kind. |

No evidence card content, number, direction of effect, subclaim level, confidence or aggregation result changed. `rests_on_non_peer_reviewed_work` remains `false`: the preprint supports a counter-test discussion and no threshold crossing depends on it.

**Rejected findings (checked, no change).** (a) Nine references carry a print/issue year one year apart from PubMed's e-publication year (refs 17, 19, 26, 32, 36, 37, 55, 56, 64); the print-year convention is used consistently and is not an error. (b) SC2 at Ζ was tested against Η: a randomised human mechanism-specific trial (CANTOS) plus human genetic and animal conditional evidence does converge, but the null all-cause mortality, the infection harm and the absence of an aging-trajectory endpoint leave an unresolved downstream contradiction within the claimed scope, so Ζ stands. (c) The bundled Β was tested against the objection that it understates SC2; weakest-link is the index rule, the sensitivity is reported, and the prose states explicitly that the bundle is not a verdict against inflammatory biology.

**Residual limitations.** Verification depth is abstract/metadata plus the four retained partial bodies; no complete-paper or supplement audit was performed by either model. One corpus item is a preprint, now labelled as such.

**Approval:** Following adversarial review and the corrections listed above, the revised document is approved. — Claude Opus 5.5 (Anthropic), 2026-10-06.

## REFERENCES

1. Gulen MF, Samson N, Keller A et al. cGAS-STING drives ageing-related inflammation and neurodegeneration. Nature. 2023. [PMID 37532932](https://pubmed.ncbi.nlm.nih.gov/37532932/). DOI: 10.1038/s41586-023-06373-1. Access: full_text_partial. Study: PMID37532932.

2. Victorelli S, Salmonowicz H, Chapman J et al. Apoptotic stress causes mtDNA release during senescence and drives the SASP. Nature. 2023. [PMID 37821702](https://pubmed.ncbi.nlm.nih.gov/37821702/). DOI: 10.1038/s41586-023-06621-4. Access: abstract_metadata. Study: PMID37821702.

3. Widjaja AA, Lim WW, Viswanathan S et al. Inhibition of IL-11 signalling extends mammalian healthspan and lifespan. Nature. 2024. [PMID 39020175](https://pubmed.ncbi.nlm.nih.gov/39020175/). DOI: 10.1038/s41586-024-07701-9. Access: full_text_partial. Study: PMID39020175.

4. Kang C, Xu Q, Martin TD et al. The DNA damage response induces inflammation and senescence by inhibiting autophagy of GATA4. Science (New York, N.Y.). 2015. [PMID 26404840](https://pubmed.ncbi.nlm.nih.gov/26404840/). DOI: 10.1126/science.aaa5612. Access: abstract_metadata. Study: PMID26404840.

5. Spadaro O, Youm Y, Shchukina I et al. Caloric restriction in humans reveals immunometabolic regulators of health span. Science (New York, N.Y.). 2022. [PMID 35143297](https://pubmed.ncbi.nlm.nih.gov/35143297/). DOI: 10.1126/science.abg7292. Access: abstract_metadata. Study: CALERIE human cohort with separate mouse PLA2G7 experiments.

6. Wang X, Li X, Ong H et al. MG53 suppresses NF-κB activation to mitigate age-related heart failure. JCI insight. 2021. [PMID 34292883](https://pubmed.ncbi.nlm.nih.gov/34292883/). DOI: 10.1172/jci.insight.148375. Access: abstract_metadata. Study: PMID34292883.

7. Agarwal P, Sampson A, Hueneman K et al. Microbial metabolite drives ageing-related clonal haematopoiesis via ALPK1. Nature. 2025. [PMID 40269158](https://pubmed.ncbi.nlm.nih.gov/40269158/). DOI: 10.1038/s41586-025-08938-8. Access: abstract_metadata. Study: PMID40269158.

8. Fielder E, Tweedy C, Wilson C et al. Anti-inflammatory treatment rescues memory deficits during aging in nfkb1-/- mice. Aging cell. 2020. [PMID 32915495](https://pubmed.ncbi.nlm.nih.gov/32915495/). DOI: 10.1111/acel.13188. Access: abstract_metadata. Study: nfkb1-null cognitive platform.

9. Krambs JR, Monlish DA, Gao F et al. Microbiota Signals Suppress B Lymphopoiesis With Aging in Mice. Frontiers in immunology. 2021. [PMID 34737755](https://pubmed.ncbi.nlm.nih.gov/34737755/). DOI: 10.3389/fimmu.2021.767267. Access: abstract_metadata. Study: PMID34737755.

10. Tichy ED, Ma N, Sidibe D et al. Persistent NF-κB activation in muscle stem cells induces proliferation-independent telomere shortening. Cell reports. 2021. [PMID 33979621](https://pubmed.ncbi.nlm.nih.gov/33979621/). DOI: 10.1016/j.celrep.2021.109098. Access: abstract_metadata. Study: PMID33979621.

11. Kang P, Liu P, Hu Y et al. NF-κB-mediated developmental delay extends lifespan in Drosophila. Proceedings of the National Academy of Sciences of the United States of America. 2025. [PMID 40339121](https://pubmed.ncbi.nlm.nih.gov/40339121/). DOI: 10.1073/pnas.2420811122. Access: abstract_metadata. Study: PMID40339121.

12. Chia JJ, Singh A, Lin YS et al. Distinct roles for NF-κB in hematopoietic stem cells and the bone marrow milieu in promoting hematopoietic aging. Cell reports. 2025. [PMID 40875292](https://pubmed.ncbi.nlm.nih.gov/40875292/). DOI: 10.1016/j.celrep.2025.116193. Access: abstract_metadata. Study: PMID40875292.

13. Allen NC, Ringler C, Woo SH et al. NF-κB-activated fibroblasts orchestrate inflammaging and emergence of pro-inflammatory granzyme K+ T cells. Immunity. 2026. [PMID 41903549](https://pubmed.ncbi.nlm.nih.gov/41903549/). DOI: 10.1016/j.immuni.2026.02.016. Access: abstract_metadata. Study: PMID41903549.

14. Hinojosa CA, Akula Suresh Babu R, Rahman MM et al. Elevated A20 contributes to age-dependent macrophage dysfunction in the lungs. Experimental gerontology. 2014. [PMID 24440463](https://pubmed.ncbi.nlm.nih.gov/24440463/). DOI: 10.1016/j.exger.2014.01.007. Access: abstract_metadata. Study: PMID24440463.

15. Tran KA, Gilbert M, Vazquez BN et al. SIRT7 regulates NUCKS1 chromatin binding to elicit metabolic and inflammatory gene expression in senescence and liver aging. Molecular cell. 2025. [PMID 40513569](https://pubmed.ncbi.nlm.nih.gov/40513569/). DOI: 10.1016/j.molcel.2025.05.025. Access: abstract_metadata. Study: PMID40513569.

16. Zhong Q, Zou Y, Liu H et al. Toll-like receptor 4 deficiency ameliorates β2-microglobulin induced age-related cognition decline due to neuroinflammation in mice. Molecular brain. 2020. [PMID 32059688](https://pubmed.ncbi.nlm.nih.gov/32059688/). DOI: 10.1186/s13041-020-0559-8. Access: abstract_metadata. Study: PMID32059688.

17. Hamann L, Ruiz-Moreno JS, Szwed M et al. STING SNP R293Q Is Associated with a Decreased Risk of Aging-Related Diseases. Gerontology. 2019. [PMID 30368497](https://pubmed.ncbi.nlm.nih.gov/30368497/). DOI: 10.1159/000492972. Access: abstract_metadata. Study: PMID30368497.

18. Arkan MC, Hevener AL, Greten FR et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nature medicine. 2005. [PMID 15685170](https://pubmed.ncbi.nlm.nih.gov/15685170/). DOI: 10.1038/nm1185. Access: abstract_metadata. Study: PMID15685170.

19. Qian F, Wang X, Zhang L et al. Age-associated elevation in TLR5 leads to increased inflammatory responses in the elderly. Aging cell. 2012. [PMID 22023165](https://pubmed.ncbi.nlm.nih.gov/22023165/). DOI: 10.1111/j.1474-9726.2011.00759.x. Access: abstract_metadata. Study: PMID22023165.

20. Maqbool A, Lattke M, Wirth T et al. Sustained, neuron-specific IKK/NF-κB activation generates a selective neuroinflammatory response promoting local neurodegeneration with aging. Molecular neurodegeneration. 2013. [PMID 24119288](https://pubmed.ncbi.nlm.nih.gov/24119288/). DOI: 10.1186/1750-1326-8-40. Access: abstract_metadata. Study: PMID24119288.

21. O'Brown ZK, Van Nostrand EL, Higgins JP et al. The Inflammatory Transcription Factors NFκB, STAT1 and STAT3 Drive Age-Associated Transcriptional Changes in the Human Kidney. PLoS genetics. 2015. [PMID 26678048](https://pubmed.ncbi.nlm.nih.gov/26678048/). DOI: 10.1371/journal.pgen.1005734. Access: abstract_metadata. Study: PMID26678048.

22. Zhang P, Catterson JH, Grönke S et al. Inhibition of S6K lowers age-related inflammation and increases lifespan through the endolysosomal system. Nature aging. 2024. [PMID 38413780](https://pubmed.ncbi.nlm.nih.gov/38413780/). DOI: 10.1038/s43587-024-00578-3. Access: abstract_metadata. Study: PMID38413780.

23. Honda S, Ikeda K, Urata R et al. Cellular senescence promotes endothelial activation through epigenetic alteration, and consequently accelerates atherosclerosis. Scientific reports. 2021. [PMID 34272458](https://pubmed.ncbi.nlm.nih.gov/34272458/). DOI: 10.1038/s41598-021-94097-5. Access: abstract_metadata. Study: PMID34272458.

24. Bektas A, Zhang Y, Lehmann E et al. Age-associated changes in basal NF-κB function in human CD4+ T lymphocytes via dysregulation of PI3 kinase. Aging. 2014. [PMID 25553802](https://pubmed.ncbi.nlm.nih.gov/25553802/). DOI: 10.18632/aging.100705. Access: abstract_metadata. Study: PMID25553802.

25. Bianchi A, Marchetti L, Hall Z et al. Moderate Exercise Inhibits Age-Related Inflammation, Liver Steatosis, Senescence, and Tumorigenesis. Journal of immunology (Baltimore, Md. : 1950). 2021. [PMID 33441438](https://pubmed.ncbi.nlm.nih.gov/33441438/). DOI: 10.4049/jimmunol.2001022. Access: abstract_metadata. Study: nfkb1-null exercise platform.

26. Jolly SS, d'Entremont MA, Lee SF et al. Colchicine in Acute Myocardial Infarction. The New England journal of medicine. 2025. [PMID 39555823](https://pubmed.ncbi.nlm.nih.gov/39555823/). DOI: 10.1056/NEJMoa2405922. Access: abstract_metadata. Study: PMID39555823.

27. Ridker PM, Libby P, MacFadyen JG et al. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). European heart journal. 2018. [PMID 30165610](https://pubmed.ncbi.nlm.nih.gov/30165610/). DOI: 10.1093/eurheartj/ehy310. Access: abstract_metadata. Study: CANTOS NCT01327846.

28. Sadjapong U, Yodkeeree S, Sungkarat S et al. Multicomponent Exercise Program Reduces Frailty and Inflammatory Biomarkers and Improves Physical Performance in Community-Dwelling Older Adults: A Randomized Controlled Trial. International journal of environmental research and public health. 2020. [PMID 32466446](https://pubmed.ncbi.nlm.nih.gov/32466446/). DOI: 10.3390/ijerph17113760. Access: abstract_metadata. Study: PMID32466446.

29. Ridker PM, MacFadyen JG, Thuren T et al. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2017. [PMID 28855077](https://pubmed.ncbi.nlm.nih.gov/28855077/). DOI: 10.1016/S0140-6736(17)32247-X. Access: abstract_metadata. Study: CANTOS NCT01327846.

30. Xu M, Pirtskhalava T, Farr JN et al. Senolytics improve physical function and increase lifespan in old age. Nature medicine. 2018. [PMID 29988130](https://pubmed.ncbi.nlm.nih.gov/29988130/). DOI: 10.1038/s41591-018-0092-9. Access: abstract_metadata. Study: PMID29988130.

31. Tyshkovskiy A, Kholdina D, Davitadze M et al. Universal transcriptomic hallmarks of mammalian ageing and mortality. Nature. 2026. [PMID 42203874](https://pubmed.ncbi.nlm.nih.gov/42203874/). DOI: 10.1038/s41586-026-10542-3. Access: abstract_metadata. Study: PMID42203874.

32. Ma LZ, Liu WS, He Y et al. Plasma proteomics identify novel biomarkers and dynamic patterns of biological aging. Journal of advanced research. 2026. [PMID 40328427](https://pubmed.ncbi.nlm.nih.gov/40328427/). DOI: 10.1016/j.jare.2025.05.004. Access: abstract_metadata. Study: PMID40328427.

33. Alpert A, Pickman Y, Leipold M et al. A clinically meaningful metric of immune age derived from high-dimensional longitudinal monitoring. Nature medicine. 2019. [PMID 30842675](https://pubmed.ncbi.nlm.nih.gov/30842675/). DOI: 10.1038/s41591-019-0381-y. Access: abstract_metadata. Study: PMID30842675.

34. Arai Y, Martin-Ruiz CM, Takayama M et al. Inflammation, But Not Telomere Length, Predicts Successful Ageing at Extreme Old Age: A Longitudinal Study of Semi-supercentenarians. EBioMedicine. 2015. [PMID 26629551](https://pubmed.ncbi.nlm.nih.gov/26629551/). DOI: 10.1016/j.ebiom.2015.07.029. Access: abstract_metadata. Study: PMID26629551.

35. Furman D, Chang J, Lartigue L et al. Expression of specific inflammasome gene modules stratifies older individuals into two extreme clinical and immunological states. Nature medicine. 2017. [PMID 28092664](https://pubmed.ncbi.nlm.nih.gov/28092664/). DOI: 10.1038/nm.4267. Access: abstract_metadata. Study: PMID28092664.

36. Lavin KM, Perkins RK, Jemiolo B et al. Effects of aging and lifelong aerobic exercise on basal and exercise-induced inflammation. Journal of applied physiology (Bethesda, Md. : 1985). 2020. [PMID 31751180](https://pubmed.ncbi.nlm.nih.gov/31751180/). DOI: 10.1152/japplphysiol.00495.2019. Access: abstract_metadata. Study: PMID31751180.

37. Marín-Aguilar F, Lechuga-Vieco AV, Alcocer-Gómez E et al. NLRP3 inflammasome suppression improves longevity and prevents cardiac aging in male mice. Aging cell. 2020. [PMID 31625260](https://pubmed.ncbi.nlm.nih.gov/31625260/). DOI: 10.1111/acel.13050. Access: abstract_metadata. Study: PMID31625260.

38. Samson LD, Boots AMH, Verschuren WMM et al. Frailty is associated with elevated CRP trajectories and higher numbers of neutrophils and monocytes. Experimental gerontology. 2019. [PMID 31336145](https://pubmed.ncbi.nlm.nih.gov/31336145/). DOI: 10.1016/j.exger.2019.110674. Access: abstract_metadata. Study: PMID31336145.

39. Cole SW, Shanahan MJ, Gaydosh L et al. Population-based RNA profiling in Add Health finds social disparities in inflammatory and antiviral gene regulation to emerge by young adulthood. Proceedings of the National Academy of Sciences of the United States of America. 2020. [PMID 32041883](https://pubmed.ncbi.nlm.nih.gov/32041883/). DOI: 10.1073/pnas.1821367117. Access: abstract_metadata. Study: PMID32041883.

40. Franck M, Tanner KT, Tennyson RL et al. Nonuniversality of inflammaging across human populations. Nature aging. 2025. [PMID 40588649](https://pubmed.ncbi.nlm.nih.gov/40588649/). DOI: 10.1038/s43587-025-00888-0. Access: abstract_metadata. Study: Four-population cytokine-axis study; Tsimane source overlap possible.

41. Cao Dinh H, Bautmans I, Beyer I et al. Association Between Immunosenescence Phenotypes and Pre-frailty in Older Subjects: Does Cytomegalovirus Play a Role? The journals of gerontology. Series A, Biological sciences and medical sciences. 2019. [PMID 29924317](https://pubmed.ncbi.nlm.nih.gov/29924317/). DOI: 10.1093/gerona/gly135. Access: abstract_metadata. Study: PMID29924317.

42. Ahuja SK, Manoharan MS, Lee GC et al. Immune resilience despite inflammatory stress promotes longevity and favorable health outcomes including resistance to infection. Nature communications. 2023. [PMID 37311745](https://pubmed.ncbi.nlm.nih.gov/37311745/). DOI: 10.1038/s41467-023-38238-6. Access: abstract_metadata. Study: PMID37311745.

43. Wikby A, Ferguson F, Forsey R et al. An immune risk phenotype, cognitive impairment, and survival in very late life: impact of allostatic load in Swedish octogenarian and nonagenarian humans. The journals of gerontology. Series A, Biological sciences and medical sciences. 2005. [PMID 15972602](https://pubmed.ncbi.nlm.nih.gov/15972602/). DOI: 10.1093/gerona/60.5.556. Access: abstract_metadata. Study: PMID15972602.

44. Brinkley TE, Leng X, Miller ME et al. Chronic inflammation is associated with low physical function in older adults across multiple comorbidities. The journals of gerontology. Series A, Biological sciences and medical sciences. 2009. [PMID 19196644](https://pubmed.ncbi.nlm.nih.gov/19196644/). DOI: 10.1093/gerona/gln038. Access: abstract_metadata. Study: PMID19196644.

45. Cao D, Huang X, Luo L et al. Elucidating causal relationships between circulating inflammatory factors and aging traits: Transcriptomics and Mendelian randomization analyses. Annals of the New York Academy of Sciences. 2025. [PMID 40864643](https://pubmed.ncbi.nlm.nih.gov/40864643/). DOI: 10.1111/nyas.70019. Access: abstract_metadata. Study: PMID40864643.

46. Kotronia E, Wannamethee SG, Papacosta AO et al. Poor Oral Health and Inflammatory, Hemostatic, and Cardiac Biomarkers in Older Age: Results From Two Studies in the UK and USA. The journals of gerontology. Series A, Biological sciences and medical sciences. 2021. [PMID 32306041](https://pubmed.ncbi.nlm.nih.gov/32306041/). DOI: 10.1093/gerona/glaa096. Access: abstract_metadata. Study: PMID32306041.

47. Yang H, Wang H, Ren J et al. cGAS is essential for cellular senescence. Proceedings of the National Academy of Sciences of the United States of America. 2017. [PMID 28533362](https://pubmed.ncbi.nlm.nih.gov/28533362/). DOI: 10.1073/pnas.1705499114. Access: abstract_metadata. Study: PMID28533362.

48. Gong Q, Sharma M, Glass MC et al. Multi-omic profiling reveals age-related immune dynamics in healthy adults. Nature. 2025. [PMID 41162704](https://pubmed.ncbi.nlm.nih.gov/41162704/). DOI: 10.1038/s41586-025-09686-5. Access: abstract_metadata. Study: PMID41162704.

49. Hao X, Zhao B, Towers M et al. TXNRD1 drives the innate immune response in senescent cells with implications for age-associated inflammation. Nature aging. 2024. [PMID 38267705](https://pubmed.ncbi.nlm.nih.gov/38267705/). DOI: 10.1038/s43587-023-00564-1. Access: abstract_metadata. Study: PMID38267705.

50. Youm YH, Grant RW, McCabe LR et al. Canonical Nlrp3 inflammasome links systemic low-grade inflammation to functional decline in aging. Cell metabolism. 2013. [PMID 24093676](https://pubmed.ncbi.nlm.nih.gov/24093676/). DOI: 10.1016/j.cmet.2013.09.010. Access: abstract_metadata. Study: PMID24093676.

51. Zhang G, Li J, Purkayastha S et al. Hypothalamic programming of systemic ageing involving IKK-β, NF-κB and GnRH. Nature. 2013. [PMID 23636330](https://pubmed.ncbi.nlm.nih.gov/23636330/). DOI: 10.1038/nature12143. Access: full_text_partial. Study: PMID23636330.

52. Aronoff JE, Jenkins CL, Garcia AR et al. Inflammaging is minimal among forager-horticulturalists in the Bolivian Amazon. Proceedings. Biological sciences. 2025. [PMID 40829666](https://pubmed.ncbi.nlm.nih.gov/40829666/). DOI: 10.1098/rspb.2025.1111. Access: abstract_metadata. Study: Tsimane/Moseten cohort; overlap with cytokine-axis study unresolved.

53. Ridker PM, Everett BM, Thuren T et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. The New England journal of medicine. 2017. [PMID 28845751](https://pubmed.ncbi.nlm.nih.gov/28845751/). DOI: 10.1056/NEJMoa1707914. Access: abstract_metadata. Study: CANTOS NCT01327846.

54. Svensson EC, Madar A, Campbell CD et al. TET2-Driven Clonal Hematopoiesis and Response to Canakinumab: An Exploratory Analysis of the CANTOS Randomized Clinical Trial. JAMA cardiology. 2022. [PMID 35385050](https://pubmed.ncbi.nlm.nih.gov/35385050/). DOI: 10.1001/jamacardio.2022.0386. Access: abstract_metadata. Study: CANTOS NCT01327846.

55. Ridker PM, MacFadyen JG, Everett BM et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet (London, England). 2018. [PMID 29146124](https://pubmed.ncbi.nlm.nih.gov/29146124/). DOI: 10.1016/S0140-6736(17)32814-3. Access: abstract_metadata. Study: CANTOS NCT01327846.

56. Ridker PM, Everett BM, Pradhan A et al. Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. The New England journal of medicine. 2019. [PMID 30415610](https://pubmed.ncbi.nlm.nih.gov/30415610/). DOI: 10.1056/NEJMoa1809798. Access: abstract_metadata. Study: PMID30415610.

57. Tardif JC, Kouz S, Waters DD et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. The New England journal of medicine. 2019. [PMID 31733140](https://pubmed.ncbi.nlm.nih.gov/31733140/). DOI: 10.1056/NEJMoa1912388. Access: abstract_metadata. Study: PMID31733140.

58. Nidorf SM, Fiolet ATL, Mosterd A et al. Colchicine in Patients with Chronic Coronary Disease. The New England journal of medicine. 2020. [PMID 32865380](https://pubmed.ncbi.nlm.nih.gov/32865380/). DOI: 10.1056/NEJMoa2021372. Access: abstract_metadata. Study: PMID32865380.

59. Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium, Swerdlow DI, Holmes MV et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet (London, England). 2012. [PMID 22421340](https://pubmed.ncbi.nlm.nih.gov/22421340/). DOI: 10.1016/S0140-6736(12)60110-X. Access: abstract_metadata. Study: PMID22421340.

60. Dou Z, Ghosh K, Vizioli MG et al. Cytoplasmic chromatin triggers inflammation in senescence and cancer. Nature. 2017. [PMID 28976970](https://pubmed.ncbi.nlm.nih.gov/28976970/). DOI: 10.1038/nature24050. Access: abstract_metadata. Study: PMID28976970.

61. Glück S, Guey B, Gulen MF et al. Innate immune sensing of cytosolic chromatin fragments through cGAS promotes senescence. Nature cell biology. 2017. [PMID 28759028](https://pubmed.ncbi.nlm.nih.gov/28759028/). DOI: 10.1038/ncb3586. Access: abstract_metadata. Study: PMID28759028.

62. Nasto LA, Seo HY, Robinson AR et al. ISSLS prize winner: inhibition of NF-κB activity ameliorates age-associated disc degeneration in a mouse model of accelerated aging. Spine. 2012. [PMID 22343279](https://pubmed.ncbi.nlm.nih.gov/22343279/). DOI: 10.1097/BRS.0b013e31824ee8f7. Access: abstract_metadata. Study: Ercc1 progeroid disc platform.

63. Tilstra JS, Robinson AR, Wang J et al. NF-κB inhibition delays DNA damage-induced senescence and aging in mice. The Journal of clinical investigation. 2012. [PMID 22706308](https://pubmed.ncbi.nlm.nih.gov/22706308/). DOI: 10.1172/JCI45785. Access: abstract_metadata. Study: Ercc1 progeroid platform.

64. Tourki B, Kain V, Pullen AB et al. Lack of resolution sensor drives age-related cardiometabolic and cardiorenal defects and impedes inflammation-resolution in heart failure. Molecular metabolism. 2020. [PMID 31918915](https://pubmed.ncbi.nlm.nih.gov/31918915/). DOI: 10.1016/j.molmet.2019.10.008. Access: full_text_partial. Study: PMID31918915.

65. Ballhysa E, Ripa R, Hochhard N et al. Loss of killifish cGAS attenuates age-related signatures but does not affect organismal life span. EMBO reports. 2026. [PMID 42717099](https://pubmed.ncbi.nlm.nih.gov/42717099/). DOI: 10.1038/s44319-026-00917-y. Access: abstract_metadata. Study: PMID42717099.

66. Hopkins JW, Sulka KB, Sawden M et al. STING promotes homeostatic maintenance of tissues and confers longevity with aging. bioRxiv : the preprint server for biology. 2024. [PMID 38645182](https://pubmed.ncbi.nlm.nih.gov/38645182/). DOI: 10.1101/2024.04.04.588107. Access: abstract_metadata. Study: PMID38645182.

67. Marión RM, González JC, Flores JM et al. STING deficiency does not rescue short telomere-mediated aging phenotypes and longevity in TERC- or TERT-telomerase deficient mice. Cell reports. 2026. [PMID 42560816](https://pubmed.ncbi.nlm.nih.gov/42560816/). DOI: 10.1016/j.celrep.2026.117786. Access: abstract_metadata. Study: PMID42560816.

68. Wissel S, Hovey KM, Andrews CA et al. Genetic interleukin-6 receptor blockade, chronic disease risk, and longevity: results from the women's health initiative. European journal of preventive cardiology. 2026. [PMID 40674461](https://pubmed.ncbi.nlm.nih.gov/40674461/). DOI: 10.1093/eurjpc/zwaf444. Access: abstract_metadata. Study: PMID40674461.

69. Jurk D, Wilson C, Passos JF et al. Chronic inflammation induces telomere dysfunction and accelerates ageing in mice. Nature communications. 2014. [PMID 24960204](https://pubmed.ncbi.nlm.nih.gov/24960204/). DOI: 10.1038/ncomms5172. Access: abstract_metadata. Study: nfkb1-null inflammatory platform.

## Source-specific evidence cards

### [1] cGAS-STING drives ageing-related inflammation and neurodegeneration.

**Shows:** STING blockade improves selected aged functions; mtDNA links damage to signaling

**Does not show:** Does not show autonomous initiation or organismal lifespan

**Access/status:** Complete primary abstract and linked-status metadata examined. Selected body sections: 2:cGAS–STING affects brain ageing, 4:mtDNA activates cGAS in aged microglia. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [2] Apoptotic stress causes mtDNA release during senescence and drives the SASP.

**Shows:** Sublethal mitochondrial permeabilization supplies DNA for SASP and functional effects

**Does not show:** Upstream apoptotic stress remains; linked correction details unexamined

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. ErratumIn: PMID38168624. Subclaims: SC2, SC3.

### [3] Inhibition of IL-11 signalling extends mammalian healthspan and lifespan.

**Shows:** Late antibody and genetic intervention improve survival and selected functions

**Does not show:** One background and incomplete genetic survival follow-up do not prove universal primacy

**Access/status:** Complete primary abstract and linked-status metadata examined. Selected body sections: 11:Discussion:paragraph3, 11:Discussion:paragraph4, 11:Discussion:paragraph5, 12:Methods:paragraph12, 12:Methods:paragraph16, 12:Methods:paragraph17, 12:Methods:paragraph22, 10:Inhibition of IL-11 extends lifespan. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [4] The DNA damage response induces inflammation and senescence by inhibiting autophagy of GATA4.

**Shows:** DNA damage GATA4 autophagy and NFkB connect injury to SASP

**Does not show:** Does not establish organismal necessity

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [5] Caloric restriction in humans reveals immunometabolic regulators of health span.

**Shows:** Human immune changes and mouse targeted metabolic effects converge

**Does not show:** Human CR is pleiotropic and mediator lifespan not tested

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

### [6] MG53 suppresses NF-κB activation to mitigate age-related heart failure.

**Shows:** MG53 improves selected heart functions with reduced inflammatory signals

**Does not show:** Repair and redox effects prevent isolated inflammation mediation

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

### [7] Microbial metabolite drives ageing-related clonal haematopoiesis via ALPK1.

**Shows:** Microbial ADP-heptose ALPK1 stimulates mutant expansion

**Does not show:** Does not establish autonomous aging initiation

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [8] Anti-inflammatory treatment rescues memory deficits during aging in nfkb1-/- mice.

**Shows:** Ibuprofen improves cognition in engineered inflammatory context

**Does not show:** Broad drug and knockout model do not establish normal-aging primacy

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [9] Microbiota Signals Suppress B Lymphopoiesis With Aging in Mice.

**Shows:** Microbiota change lineage aging despite nonuniform inflammatory signatures

**Does not show:** Germ-free development and ecology differ

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [10] Persistent NF-κB activation in muscle stem cells induces proliferation-independent telomere shortening.

**Shows:** Persistent NFkB affects telomeres and muscle dysfunction

**Does not show:** Chronic injury scope is distinct from normal organismal aging

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [11] NF-κB-mediated developmental delay extends lifespan in Drosophila.

**Shows:** Timed Relish and PTTH manipulation affects life and inflammatory programs

**Does not show:** Developmental timing is a separate upstream intervention

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [12] Distinct roles for NF-κB in hematopoietic stem cells and the bone marrow milieu in promoting hematopoietic aging.

**Shows:** Intrinsic NFkB and inflammatory niche drive distinct HSC defects

**Does not show:** Elevated signaling is not sufficient for every aging hallmark

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. UpdateOf: PMID39868295. Subclaims: SC2, SC3.

### [13] NF-κB-activated fibroblasts orchestrate inflammaging and emergence of pro-inflammatory granzyme K+ T cells.

**Shows:** Fibroblast NFkB and GZMK T-cell depletion alter injury vulnerability

**Does not show:** Does not establish systemic aging initiation or life extension

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [14] Elevated A20 contributes to age-dependent macrophage dysfunction in the lungs.

**Shows:** TNF-A20 mechanism links chronic inflammation to weak antibacterial response

**Does not show:** Diet and local response do not isolate whole-organism aging

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

### [15] SIRT7 regulates NUCKS1 chromatin binding to elicit metabolic and inflammatory gene expression in senescence and liver aging.

**Shows:** SIRT7 loss and chromatin binding connect senescence to inflammation

**Does not show:** Not a lifespan or primary-initiation test

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. UpdateOf: PMID38370824. Subclaims: SC2, SC3.

### [16] Toll-like receptor 4 deficiency ameliorates β2-microglobulin induced age-related cognition decline due to neuroinflammation in mice.

**Shows:** TLR4 deficiency attenuates induced cognitive phenotypes

**Does not show:** Injected B2M model and unexamined erratum limit scope

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. ErratumIn: PMID38654273. Subclaims: SC2.

### [17] STING SNP R293Q Is Associated with a Decreased Risk of Aging-Related Diseases.

**Shows:** Hypomorphic variant associates with selected disease risk

**Does not show:** Association and subgroup effects do not establish organismal causation

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

### [18] IKK-beta links inflammation to obesity-induced insulin resistance.

**Shows:** Cell-specific perturbation alters insulin resistance

**Does not show:** Developmental and metabolic context not systemic aging initiation

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

### [19] Age-associated elevation in TLR5 leads to increased inflammatory responses in the elderly.

**Shows:** Age-related TLR5 response rises with incomplete NFkB activation

**Does not show:** Not all immune responses increase and no in vivo dependency

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

### [20] Sustained, neuron-specific IKK/NF-κB activation generates a selective neuroinflammatory response promoting local neurodegeneration with aging.

**Shows:** Persistent activation drives local dysfunction partially reversible on cessation

**Does not show:** Selected neural scope not autonomous organismal aging

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

### [21] The Inflammatory Transcription Factors NFκB, STAT1 and STAT3 Drive Age-Associated Transcriptional Changes in the Human Kidney.

**Shows:** Inflammatory transcription and variants associate with renal decline

**Does not show:** Cell stimulation and genetic association do not prove general initiation

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

### [22] Inhibition of S6K lowers age-related inflammation and increases lifespan through the endolysosomal system.

**Shows:** Midlife IMD repression extends life with TOR-related sex effects

**Does not show:** mTOR and lysosomal context remain upstream or interacting

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [23] Cellular senescence promotes endothelial activation through epigenetic alteration, and consequently accelerates atherosclerosis.

**Shows:** Senescence produces hyperinflammatory adhesion and faster atherosclerosis

**Does not show:** Progeroid injury precedes response and is not normal-aging primacy

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [24] Age-associated changes in basal NF-κB function in human CD4+ T lymphocytes via dysregulation of PI3 kinase.

**Shows:** Basal NFkB age differences linked to metabolic PI3K activity

**Does not show:** Ex vivo manipulation not in vivo organismal necessity

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

### [25] Moderate Exercise Inhibits Age-Related Inflammation, Liver Steatosis, Senescence, and Tumorigenesis.

**Shows:** Exercise reduces inflammation and liver pathology

**Does not show:** Multiple metabolic and repair actions do not isolate mediator

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

### [26] Colchicine in Acute Myocardial Infarction.

**Shows:** Colchicine lowers CRP but primary cardiovascular outcome is null

**Does not show:** Clinical disease context and broad drug do not refute all inflammatory pathways

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [27] Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS).

**Shows:** Achieved IL6 associates with lower clinical risk

**Does not show:** Response-defined subgroup is not independently randomized or replication

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

### [28] Multicomponent Exercise Program Reduces Frailty and Inflammatory Biomarkers and Improves Physical Performance in Community-Dwelling Older Adults: A Randomized Controlled Trial.

**Shows:** Frailty and function improve with inflammatory biomarker reduction

**Does not show:** Exercise efficacy does not establish inflammation mediation

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

### [29] Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.

**Shows:** Incident lung-cancer signals accompany IL1 blockade

**Does not show:** Exploratory same-cohort analysis and infection harm limit inference

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

### [30] Senolytics improve physical function and increase lifespan in old age.

**Shows:** Added burden and clearance affect function and remaining survival

**Does not show:** Does not isolate inflammation from all cell functions

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [31] Universal transcriptomic hallmarks of mammalian ageing and mortality.

**Shows:** Inflammatory mortality modules recur with modular intervention responses

**Does not show:** Predictive clocks do not establish causal rate control

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

### [32] Plasma proteomics identify novel biomarkers and dynamic patterns of biological aging.

**Shows:** Proteins and genetic instruments associate with aging phenotypes

**Does not show:** Instrument assumptions and surrogate phenotypes do not establish primacy

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

### [33] A clinically meaningful metric of immune age derived from high-dimensional longitudinal monitoring.

**Shows:** Immune trajectories predict mortality with interindividual variation

**Does not show:** Prediction does not establish initiating mechanism

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

### [34] Inflammation, But Not Telomere Length, Predicts Successful Ageing at Extreme Old Age: A Longitudinal Study of Semi-supercentenarians.

**Shows:** Inflammation predicts survival and function at extreme ages

**Does not show:** Survivor selection and residual confounding remain

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

### [35] Expression of specific inflammasome gene modules stratifies older individuals into two extreme clinical and immunological states.

**Shows:** Nucleotide metabolites activate inflammasomes and selected vascular phenotypes

**Does not show:** Does not establish the primary aging trigger

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

### [36] Effects of aging and lifelong aerobic exercise on basal and exercise-induced inflammation.

**Shows:** Exercise history associates with inflammatory and muscle-response profiles

**Does not show:** Activity selection and multiple mechanisms prevent mediation inference

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

### [37] NLRP3 inflammasome suppression improves longevity and prevents cardiac aging in male mice.

**Shows:** Knockout preserves cardiac features and survival

**Does not show:** Developmental male one-background result is not universal aging primacy

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

### [38] Frailty is associated with elevated CRP trajectories and higher numbers of neutrophils and monocytes.

**Shows:** Frailty accompanies persistently elevated CRP and myeloid cells

**Does not show:** Age CRP slope differs by sex; association is not initiation

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

### [39] Population-based RNA profiling in Add Health finds social disparities in inflammatory and antiviral gene regulation to emerge by young adulthood.

**Shows:** Social and behavioral variation in immune signals precedes old age

**Does not show:** Does not isolate a causal exposure or aging rate

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

### [40] Nonuniversality of inflammaging across human populations.

**Shows:** Cytokine axes and age associations vary by population

**Does not show:** Chosen cytokine-axis nonuniversality does not prove absence of all tissue inflammation

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

### [41] Association Between Immunosenescence Phenotypes and Pre-frailty in Older Subjects: Does Cytomegalovirus Play a Role?

**Shows:** IL6 but not CMV seropositivity associates with prefrailty

**Does not show:** Does not establish causal inflammatory primacy

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

### [42] Immune resilience despite inflammatory stress promotes longevity and favorable health outcomes including resistance to infection.

**Shows:** Immune balance associates with survival and infection outcomes

**Does not show:** Metrics and cohorts are not independent causal interventions

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

### [43] An immune risk phenotype, cognitive impairment, and survival in very late life: impact of allostatic load in Swedish octogenarian and nonagenarian humans.

**Shows:** Immune phenotype and cognition predict survival

**Does not show:** Persistent virus and cognitive pathology complicate cause

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

### [44] Chronic inflammation is associated with low physical function in older adults across multiple comorbidities.

**Shows:** CRP and IL6 associate with physical function

**Does not show:** Cross-sectional adjusted relationships do not resolve direction

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

### [45] Elucidating causal relationships between circulating inflammatory factors and aging traits: Transcriptomics and Mendelian randomization analyses.

**Shows:** Forward and reverse instrument associations support heterogeneous links

**Does not show:** Pleiotropy overlap and aging-surrogate definitions constrain causal direction

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

### [46] Poor Oral Health and Inflammatory, Hemostatic, and Cardiac Biomarkers in Older Age: Results From Two Studies in the UK and USA.

**Shows:** Oral-health burden associates with inflammatory biomarkers

**Does not show:** Cross-sectional oral injury context does not isolate mechanism

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

### [47] cGAS is essential for cellular senescence.

**Shows:** cGAS loss alters damage-induced senescence and immortalization

**Does not show:** Tumor suppression can be beneficial; cellular scope not systemic aging

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [48] Multi-omic profiling reveals age-related immune dynamics in healthy adults.

**Shows:** Some age-related T-cell reprogramming is not driven by systemic inflammation or CMV

**Does not show:** Does not rule out other inflammatory aging components; correction details unexamined

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. UpdateOf: PMID39314416; ErratumIn: PMID41963685. Subclaims: SC1, SC3.

### [49] TXNRD1 drives the innate immune response in senescent cells with implications for age-associated inflammation.

**Shows:** Interaction-specific inhibition reduces selected inflammatory markers

**Does not show:** Marker reduction and tumor context do not prove life extension

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [50] Canonical Nlrp3 inflammasome links systemic low-grade inflammation to functional decline in aging.

**Shows:** Defined sensor loss alters multi-organ aging functions with mediator differences

**Does not show:** Developmental deletion and upstream damage sensing do not prove autonomy

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [51] Hypothalamic programming of systemic ageing involving IKK-β, NF-κB and GnRH.

**Shows:** Adult gain-loss contrasts affect survival and functions; GnRH branch implicated

**Does not show:** Region-specific potency and broad developmental knockout do not establish universal primacy

**Access/status:** Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Pro- and anti-aging by hypothalamic IKKβ/NF-κB activation or inhibition, 4:Genetic longevity by suppressing brain IKKβ. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [52] Inflammaging is minimal among forager-horticulturalists in the Bolivian Amazon.

**Shows:** Minimal selected inflammaging in Tsimane differs from market-integrated neighbors

**Does not show:** Mostly cross-sectional; IL6 still increases and tissue inflammation unmeasured

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

### [53] Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.

**Shows:** Specific blockade reduces recurrent cardiovascular events without lipid lowering

**Does not show:** No all-cause survival benefit; infection harm and disease-selected scope

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [54] TET2-Driven Clonal Hematopoiesis and Response to Canakinumab: An Exploratory Analysis of the CANTOS Randomized Clinical Trial.

**Shows:** TET2 subgroup suggests enhanced response with nonsignificant interaction

**Does not show:** Not independently randomized subgroup or new clinical replication

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

### [55] Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial.

**Shows:** Lower achieved CRP accompanies larger risk reduction

**Does not show:** Post-treatment conditioning limits causal mediation and survival inference

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

### [56] Low-Dose Methotrexate for the Prevention of Atherosclerotic Events.

**Shows:** Cardiovascular outcomes and specified inflammatory markers do not improve

**Does not show:** Without pathway engagement this is not a clean falsification of IL1 IL6 causality

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

### [57] Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction.

**Shows:** Colchicine reduces selected post-MI composite events

**Does not show:** Broad drug and pneumonia signal; not general aging efficacy

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

### [58] Colchicine in Patients with Chronic Coronary Disease.

**Shows:** Colchicine reduces chronic-coronary composite events

**Does not show:** No general healthy-life claim; noncardiovascular mortality uncertainty

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

### [59] The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis.

**Shows:** IL6R variant and biomarker pattern support coronary causal role

**Does not show:** Pooled original genetic analysis is not aging initiation or longevity proof

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

### [60] Cytoplasmic chromatin triggers inflammation in senescence and cancer.

**Shows:** Cytoplasmic chromatin triggers cGAS inflammation with surveillance role

**Does not show:** Upstream DNA and cancer context block autonomous-aging inference

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [61] Innate immune sensing of cytosolic chromatin fragments through cGAS promotes senescence.

**Shows:** cGAS recognizes fragments and promotes paracrine senescence

**Does not show:** Damage precedes inflammation; no organismal-life test

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [62] ISSLS prize winner: inhibition of NF-κB activity ameliorates age-associated disc degeneration in a mouse model of accelerated aging.

**Shows:** Genetic and drug NFkB suppression improve disc measures

**Does not show:** Shared progeroid platform and unexamined erratum limit generalization

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. ErratumIn: PMIDnot supplied. Subclaims: SC2.

### [63] NF-κB inhibition delays DNA damage-induced senescence and aging in mice.

**Shows:** Genetic and drug inhibition reduce damage-driven aging phenotypes

**Does not show:** Upstream repair defect remains; not autonomous normal-aging initiation

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [64] Lack of resolution sensor drives age-related cardiometabolic and cardiorenal defects and impedes inflammation-resolution in heart failure.

**Shows:** Resolution loss produces sex-specific obesity and early mortality

**Does not show:** Survival comparison includes assumed normal lifespan; severe early model not normal senescence

**Access/status:** Complete primary abstract and linked-status metadata examined. Selected body sections: 2:Methods:paragraph5, 3:Results:paragraph1, 3:Results:paragraph2, 3:Results:paragraph3, 2:Methods. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [65] Loss of killifish cGAS attenuates age-related signatures but does not affect organismal life span.

**Shows:** Age signatures improve while lifespan remains unchanged

**Does not show:** Compensation and developmental loss differ from timed selective blockade

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [66] STING promotes homeostatic maintenance of tissues and confers longevity with aging.

**Shows:** STING deficiency shortens life and disrupts homeostasis

**Does not show:** Basal lifelong loss does not negate pathological late activation

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. bioRxiv preprint (PubMed publication type "Preprint"); not peer reviewed and not used to carry a threshold crossing. Subclaims: SC2, SC3.

### [67] STING deficiency does not rescue short telomere-mediated aging phenotypes and longevity in TERC- or TERT-telomerase deficient mice.

**Shows:** STING loss fails to rescue several degenerative and survival phenotypes

**Does not show:** Bounded telomerase context not all aging

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [68] Genetic interleukin-6 receptor blockade, chronic disease risk, and longevity: results from the women's health initiative.

**Shows:** Tested IL6R allele does not predict survival to90 or major disease outcomes

**Does not show:** Single variant female cohort does not duplicate drug blockade or refute all inflammation causality

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [69] Chronic inflammation induces telomere dysfunction and accelerates ageing in mice.

**Shows:** Inflammatory genetic state causes ROS telomere feedback and reduced repair

**Does not show:** Engineered inflammation sufficiency does not establish normal-aging primary initiation

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.